 |
|
|
Russo Partners in the News.
 |
 |
|
Anthera Pharmaceuticals Hires Russo Partners to Construct and Implement Corporate Communications Program
Date: February 15, 2012
Summary: Anthera Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing products to treat cardiovascular and autoimmune diseases, has hired Russo Partners to construct and implement a corporate communications program. The program will involve messaging creation and media relations to raise awareness of Anthera's lead product candidates in acute coronary syndrome and systemic lupus erythematosus. |
|
|
|
 |
|
Russo Partners Initiates Media Relations Program for Adynxx
Date: January 13, 2012
Summary: Russo Partners has kicked off a media relations program with Adynxx, a company based in San Francisco that is focused on developing solutions for chronic pain. They will work with Adynxx to help 'raise the curtain' with publicity around initiation of its clinical programs, key management hires and financing. |
|
|
|
 |
|
NABsys selects Russo Partners for Corporate Communications Program
Date: December 15, 2011
Summary: NABsys, a life sciences company working at the intersection of physics, biology and computer science to revolutionize medicine through clinical-grade whole-genome DNA sequencing, has selected Russo Partners to develop and implement a corporate communications program. The program will involve messaging development and media relations to raise awareness of NABsys' new way of sequencing the human genome for diagnostic and basic research applications. |
|
|
|
 |
|
Ambit Biosciences Inc. Initiates Corporate Communications Program with Russo Partners
Date: November 22, 2011
Summary: Ambit Biosciences, a biopharmaceutical company engaged in the development of small molecule kinase inhibitors for the treatment of cancer and other diseases, has hired Russo Partners to construct and implement a corporate communications program. The program will involve messaging creation, media relations and investor relations to raise awareness of Ambit's lead drug candidate intended for the treatment of acute myeloid leukemia, quizartinib, and robust pipeline. |
|
|
|
 |
|
Russo Partners will be managing media activities for BIOCOM's Second Annual Global Life Science Partnering Conference
Date: November 10, 2011
Summary: Russo Partner will be managing the media activities for BIOCOM's Second Annual Global Life Science Partnering Conference. The event is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies. |
|
|
|
 |
|
Russo Partners handling media relations for The Life Sciences Summit 2011
Date: November 9, 2011
Summary: Russo Partner is handling media relations for The Life Sciences Summit 2011. The Life Sciences Summit 2011 features breakthrough companies and next-generation technologies that collectively represent the future of the industry, and brings together key opinion leaders who share the goal of bringing new therapeutic options to patients. |
|
|
|
 |
|
Russo Partners Initiates Media Relations Program for Thrombolytic Science International (TSI)
Date: October 25, 2011
Summary: Russo Partners has kicked off a media relations program for TSI, a company focused on developing M5, a pro-urokinase mutant with improved stability over its endogenous parent compound. M5 is a novel compound with improved safety and efficacy over currently available thrombolytic therapy, particularly with regard to bleeding risk. TSI expects this advantageous profile will expand the treatment window as well as increase the population of patients who are eligible to receive thrombolytic therapy based on timing and geographic location for both heart attack and stroke. |
|
|
|
 |
|
Russo Partners Kicks Off Communications Program for Puma Biotechnology
Date: October 24, 2011
Summary: Russo Partners has kicked off a communications program for Puma Biotechnology, Inc., a development-stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. |
|
|
|
 |
|
Russo Partners' client, Cellular Dynamics International, named Gold Winner of the 2011 Wall Street Journal Technology Innovation Awards
Date: October 19, 2011
Summary: Cellular Dynamics International (CDI), a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications, has been named as the Gold Winner of the 2011 Wall Street Journal Technology Innovation Awards. The awards are determined by an independent panel of judges that reviewed 605 applicants from 16 industrial categories. Russo Partners worked with CDI to develop the messages that clearly articulate the value of their technology and products. That messaging was incorporated into the award application. |
|
|
|
 |
|
Flexion Therapeutics hires Russo Partners to construct and implement a public relations program
Date: September 26, 2011
Summary: Flexion Therapeutics, a biopharmaceutical company developing targeted therapies for the treatment of osteoarthritis and other painful conditions, has hired Russo Partners to construct and implement a public relations program. The program will involve messaging creation, media relations and investor relations to raise awareness of Flexion’s best in class pipeline of novel, sustained release intra-articular therapies for osteoarthritis. |
|
|
|
|
|
Russo Partners Set to Open New Manhattan Office on Oct. 1 to Accommodate Recent, Projected Growth
Date: September 20, 2011
Summary: The firm will open a new office on Oct. 1 that occupies the entire fourth floor of 12 West 27th Street in New York City. This move reflects the firms recent and projected growth, enabling Russo Partners to add more account services professionals and support staff in 2012. |
|
|
|
|
|
Genervon, LIFE Biosystems Join Russo Partners’ Client Roster
Date: September 16, 2011
Summary: Genervon of Pasadena, Calif., and LIFE Biosystems of Basel, Switzerland, and Houston are the latest additions to the Russo Partners client roster. For more information about each life sciences company, visit www.genervon.com and www.lifbiosystems.com. (Elliot: Make sure you check the links to see that they work.) |
|
|
|
|
|
Russo Partners Names Cindy McGee and Robert Flamm, Ph.D., as Vice Presidents
Date: September 14, 2011
Summary: Russo Partners has named Cindy McGee and Robert Flamm, Ph.D., as vice presidents. Cindy, who is based in San Diego, has joined the agency from Arena Pharmaceuticals, where she led the company's investor relations and corporate communications program. She will manage client programs and business-development initiatives in the West. Robert, a former biotechnology securities analyst who is based in New York City, has served as an Assistant Vice President of Russo Partners. He will continue to oversee client programs as well as business-development activities in the East. |
|
|
|
 |
|
Russo Partners initiates media relations program for Medhattan Immediate Medical Care
Date: August 1, 2011
Summary: Russo Partners has launched a media relations program to support the opening of Medhattan's innovative immediate medical care facility in lower Manhattan. Russo Partners is focusing on national, regional and local neighborhood media coverage for the facilit's opening in September 2011. |
|
|
|
|
|
Russo Partners Expands West Coast Operations, Moves Office to Downtown San Diego
Date: July 12, 2011
Summary:Russo Partners has moved its West Coast office to downtown San Diego as part of the firm’s recent expansion. The office, which is located at 696 State Street, serves as Russo Partners base for work with emerging healthcare companies in the West. |
|
|
|
|
|
Russo Partners’ Tony Russo to present at the Edmond de Rothschild Investment Partners Life Sciences Seminar
Date: June 21, 2011
Summary: Tony Russo, chairman and CEO of Russo Partners, will be presenting at the Edmond de Rothschild Investment Partners Life Sciences Seminar being held on June 23 – 24 at Saint-Jean-Cap-Ferrat in France. His presentation will focus on the importance of critical communication strategies, including messaging and positioning, for biotech companies interacting with the media. |
|
|
|
|
|
Russo Partners' David Schull to speak about communications best practices at ABFO Annual Meeting
Date: May 25, 2011
Summary: David Schull, president of Russo Partners, will participate in a panel discussion about communications best practices at the ABFO Annual Meeting on June 2 in Seattle. His presentation will focus on case studies involving biotech companies' reporting of late-stage clinical trial data.
|
|
|
|
 |
|
Russo Partners Kicks Off Media Relations Program to Raise Probiodrug’s Visibility in the U.S.
Date: April 21, 2011
Summary: Russo Partners has kicked off a U.S. media relations program for Probiodrug, a company based in Halle, Germany, that is dedicated to the discovery and development of innovative small molecule drugs against novel molecular targets for the treatment of neuronal and inflammatory diseases. Probiodrug has a dominant position in the area of glutaminyl cyclase (QC) inhibitors – QC is a novel enzyme target that has a crucial role in the pathogenesis of Alzheimer’s disease. |
|
|
|
 |
|
Endocyte Selects Russo Partners for Public Relations Support
Date: April 20, 2011
Summary: Endocyte, a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases, has hired Russo Partners to develop and implement a public relations program. The program will involve media relations, key opinion leader outreach and advocacy group activities to raise awareness of Endocyte’s small molecule drug conjugates, or SMDCs, and companion imaging diagnostics in development. |
|
|
|
 |
|
Bill Newell, CEO of South San Francisco-based Sutro Biopharma, will be a panel participant in Xconomy’s Forum: Bay Area Life Sciences 2031
Date: March 16, 2011
Summary: Bill Newell of Sutro Biopharma will join entrepreneurs from the San Francisco area to discuss why their companies’ innovations will still be relevant in 2031. The Xconomy forum will be held March 16, from 5 p.m. to 8:30 p.m. PDT, at UCSF’s Mission Bay campus, Genentech Hall. Sutro Biopharma is a biopharmaceutical company developing novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. |
|
|
|
 |
|
Russo Partners Adds Toronto-based Cynapsus to Client Roster
Date: February 4, 2011
Summary: Russo Partners has added Cynapsus, a drug development company focused on Parksinson’s disease and other CNS indications, to the client roster. Launched this month, the Cynapsus public relations program consists of message development, media relations and executive visibility activities.
|
|
|
|
 |
|
Polaris Group Selects Russo Partners for Public Relations Services
Date: February 3, 2011
Summary: San Diego-based Polaris Group, a biopharmaceutical company, has selected Russo Partners for the provision of public relations services. Russo Partners is focusing on message development and media relations to support Polaris Group’s investor targeting initiatives. |
|
|
|
 |
|
Russo Partners Kicks Off Communications Program for GlycoVaxyn
Date: January 10, 2011
Summary: Russo Partners has kicked off a U.S. investor-focused communications program for Swiss vaccine company GlycoVaxyn. |
|
|
|
 |
|
MWW looks for long-term growth with independence
Date: January 7, 2011
Summary: MWW Group is the most recent of a small handful of wholly or partially owned PR agencies that have bought back full independence from holding companies, in large part for entrepreneurial freedom and control over growth strategy. |
|
|
|
 |
|
TetraLogic Pharmaceuticals Selects Russo Partners as PR Agency of Record
Date: January 7, 2011
Summary: Malvern, Pa.-based TetraLogic Pharmaceuticals has selected Russo Partners as PR agency of record. Russo Partners is implementing a media relations campaign to highlight the promise of Smac mimetics for the treatment of cancer. |
|
|
|
|
|
Russo Partners Coordinates West Coast Biotech/Pharma Collaboration Roundtable for Pharmaceutical Executive Magazine
Date: November 8, 2010
Summary: Russo Partners organized and coordinated a CEO roundtable at the offices of BIOCOM in San Diego. Participants included Bob Baltera, president and CEO of Amira Pharmaceuticals, Inc., Kathy Bowdish, president and CEO of Anaphore Pharmaceuticals, Inc., Jay Lichter, managing director of Avalon Ventures, Margi McLoughlin, senior director R&D Business Development of Pfizer, Inc., Kleanthis Xanthopoulos, president and CEO of Regulus Therapeutics, Inc., and Bill Newell, CEO of Sutro Biopharma, Inc. |
|
|
|
 |
|
German biotech company CureVac turns to Russo Partners for U.S. public relations support
Date: October 11, 2010
Summary: CureVac, a biotechnology company based in Tuebingen, Germany, that is developing messenger RNA-based vaccines, has turned to Russo Partners for counsel in publicizing clinical trial data for a prostate cancer immunotherapy in the United States. CureVac joins other companies, including MorphoSys, QIAGEN and febit, headquartered in Germany that work with Russo Partners to raise their visibility among U.S. target audiences of investors, business partners and members of the scientific and medical communities. |
|
|
|
 |
|
Russo Partners rolls out proactive media relations initiatives for Idera Pharmaceuticals
Date: October 6, 2010
Summary: Russo Partners is rolling out proactive media relations initiatives for Idera Pharmaceuticals as the company prepares to present clinical trial data for its immune modulator for the treatment of chronic hepatitis C infection at the Liver Meeting 2010. Idera’s proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses.
|
|
|
|
 |
|
Reata Pharmaceuticals hires Russo Partners for media relations program
Date: October 5, 2010
Summary: Reata Pharmaceuticals, which is developing anti-inflammatory drugs, has hired Russo Partners to implement a U.S. media relations program. The agency is focusing on the development of relationships for Reata’s executives with biotechnology and pharmaceuticals reporters with business and trade media outlets in conjunction with the distribution of partnership and publication news. |
|
|
|
|
|
Anaphore picks Russo
Date: August 9, 2010
Summary: LA JOLLA, CA: Anaphore hired Russo Partners to develop a corporate communications program, effective August 1. The program aims to raise awareness about the protein therapeutics the biopharmacuetical company is developing. |
|
|
|
 |
|
Russo Partners Expands Client Roster in San Diego with Addition of Anaphore
Date: August 4, 2010
Summary: Russo Partners has expanded its client roster in San Diego with the addition of Anaphore, a biopharmaceutical company. The agency is rolling out a corporate communications program to raise awareness of the company’s protein therapeutic development technology. |
|
|
|
|
|
Russo wins two clients
Date: July 21, 2010
Summary: NEW YORK: Russo Partners added two clients: Argos Therapeutics and LifeCycle Pharma. The firm is providing corporate communications for Argos' personalized immunotherapy platform and IR support for LifeCyle Pharma. |
|
|
|
 |
|
Argos Therapeutics Selects Russo Partners to Raise Visibility of Immunotherapy Platform
Date: July 15, 2010
Summary: Argos Therapeutics has selected Russo Partners to establish corporate communication tactics for their Arcelis personalized immunotherapy platform. Argos’ Arcelis program has been developed to better harness the strength of dendritic cells to treat cancer, HIV and other infectious diseases by loading these cells with a patient’s own tumor or viral RNA. Based out of Durham, North Carolina, Argos Therapeutics is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. |
|
|
|
 |
|
Russo Partners Joins with LifeCycle Pharma to Strengthen Investor Communications
Date: July 14, 2010
Summary: Russo Partners has been brought on by LifeCycle Pharma to help strengthen the company’s messaging and positioning with its key audience: investors. The main goal is to attract new investors to the company. LifeCycle Pharma is based in Hørsholm, Denmark, with an office in New York City, and is an emerging pharmaceutical company with an organ transplant compound in Phase 3 clinical trials.
|
|
|
|
 |
|
Russo Partners Initiates Media Relations Efforts for Ascalon International
Date: June 3, 2010
Summary: Russo Partners has initiated a media relations campaign for Scottsdale, Ariz.-based oncology drug development company Ascalon International. Ascalon was established in June 2009 to create and manage a diversified portfolio of promising oncology drugs using cutting-edge development methodologies pioneered by the company’s management team and capitalize on the growing trend in the pharmaceutical industry for strategic outsourcing. of |
|
|
|
 |
|
Russo Partners Kicks Off PR Initiatives for Aragon Pharmaceuticals
Date: April 14, 2010
Summary: Russo Partners has kicked off PR initiatives for San Diego-based Aragon Pharmaceuticals. The company is focused on developing a pipeline of new anti-endocrine therapies targeting the biology of hormone-resistant cancers. |
|
|
|
|
|
ReVision Therapeutics Names Russo Partners Agency of Record
Date: April 5, 2010
Summary: San Diego-based ReVision Therapeutics has named Russo Partners as public relations agency of record. Russo Partners kicked off a communication program consisting of message development, media relations and corporate visibility initiatives on April 1 for this drug-development company that is focusing on treatments for age-related macular degeneration. |
|
|
|
 |
|
Russo Partners Adds Seattle Genome Sequencing Technology Company to Client Roster
Date: March 25, 2010
Summary: Seattle-based Stratos Genomics Inc. has selected Russo Partners to handle public relations projects. Stratos Genomics is a spin-out of Seattle-based Stratos Group LLC, which is dedicated to the conversion of science and technology into commercial solutions for the advancement of mankind and the protection of the environment. Also under the Stratos Group umbrella is Stratos Product Development LLC, a world leader in high tech product development services.
|
|
|
|
 |
|
Russo Partners to Handle Media Relations for Celladon
Date: March 17, 2010
Summary: Russo Partners will kick off media relations initiatives for La Jolla, Calif.-based Celladon, a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational and technologically sophisticated approaches to cardiovascular treatments. The company’s first product candidate is designed to target the key enzyme deficiency in advanced heart failure that regulates calcium cycling and contractility in heart muscle cells. |
|
|
|
 |
|
SCRM Hires Russo Partners for Groundbreaking Ceremony PR
Date: March 5, 2010
Summary: Russo Partners has been hired by the Sanford Consortium for Regenerative Medicine to lead public relations activities for its groundbreaking ceremony in March. These activities will include development of key messages, spokesperson training and media relations activities around the groundbreaking ceremony. The Sanford Consortium for Regenerative Medicine is a nonprofit organization that brings together intellectual resources of four world-leaders in life sciences research: the Burnham Institute for Medical Research, the Salk Institute for Biological Studies, The Scripps Research Institute and the University of California, San Diego. Using the collective strength of its members, the Consortium’s research program is focused on developing tools and technologies to hasten the pace of stem cell research progress and to discover and develop diagnostics, therapies and cures to relieve human suffering from chronic disease and injury. |
|
|
|
 |
|
MedAssurant Selects Russo Partners to Implement National PR Program
Date: March 3, 2010
Summary: MedAssurant, a leading provider of data-driven healthcare solutions, has selected Russo Partners to develop and implement a national public relations program. The program will consist of message and positioning development, media relations and key opinion leader communications to support the company’s brand-building and sales initiatives. MedAssurant provides local, regional and nationwide health insurance plans, hospitals, pharmaceutical companies, regulatory bodies, government organizations, physician organizations and their many covered patients with powerful turnkey solutions to address matters of clinical outcomes analysis, quality of care, cost improvement, risk adjustment, disease management, utilization and healthcare data verification. Altogether, MedAssurant solutions are provided to more than 200 healthcare organizations, supporting more than 100 million Americans.
|
|
|
|
|
|
|
David Schull to Participate on Panel – CEO Lyceum: The Process of Raising Capital in the Life Sciences Industry – at La Costa Resort and Spa, Carlsbad, Calif.
Date: October 23, 2009
Summary: Join David Schull at 3:30 p.m. PDT on Friday, Oct. 23, at CEO Lyceum at the La Costa Resort and Spa, Carlsbad, Calif. The president of Russo Partners, David will participate on a panel of experts on the process of raising capital in the life sciences industry and how to best position a company and its science to maximize visibility. Panelists will include four experts in the field: George Scangos, CEO and president of Exelixis; Bob More, general partner of Frazier Healthcare Ventures; Gaylene Xanthopoulos, president of The Leadership Edge; Doug Wheeler, co-owner & partner of Summit Performance Group.
For more information, click here: http://tinyurl.com/yzukyd5
|
|
|
|
|
|
|
Tony Russo to Chair Panel – Getting on the MAP: Messaging and Positioning Towards Negotiations – at AdvaMed 2009
Date: October 7, 2009
Summary: Join Tony Russo at 9:30 a.m. on Wednesday, Oct. 14, at AdvaMed 2009 in Washington. The founder of Russo Partners, Tony will chair a panel that focuses on approaches executives with medtech companies have taken to refine their company and product messages for business development purposes. Panelists will include three executives with whom Russo Partners has worked closely: S. Eric Ryan, M.D., chairman and CEO, CorNova; Patrick Daly, president and CEO, Cohera Medical; and Al Novak, president and CEO, OrbusNeich.
For more information, click here: http://www.advamed2009.com/go.cfm?do=Panel.View&pdid=9&track=Development
|
|
|
|
 |
|
Building an Effective Communication Program - Tony Russo, Ph.D.
Date: August 11, 2009
Summary: Over my 25 years in public and investor relations, I have seen many bull and bear markets. I witnessed the great bull leading up to the crash of ’87, the recovery of ’88, the exceptionally strong biotech markets beginning in ’95, and the extreme bull market of ’99, followed by the lackluster years of the current decade. Through the good times as well as the bad, there has always been one dictum among companies in the biotech sector: spend money on public and investor relations when times are good and conserve cash when the times are hard. This strategy makes sense on a basic level. Cash-strapped biotech companies need to watch their money, and PR and IR are seen as nonessential. But what can be more fundamental to raising money than maintaining a strong profile and leadership image in a given sector?
http://www.genengnews.com/articles/chitem.aspx?aid=2986&chid=0
|
|
|
|
|
|
|
Biomatrica names Russo Partners as AOR - Jaimy Lee
Date: April 23, 2009
Summary: SAN DIEGO: Biomatrica, a lab sample technology developer, tapped Russo Partners as its AOR, effective April 13. The firm is providing media relations and aims to raise awareness of the San Diego-based company's products with the life sciences audience.
|
|
|
|
|
|
|
Biotech companies tout their value - Jaimy Lee
Date: March 23, 2009
Summary: In an environment full of possible acquisitions and partnership deals, biotech companies are making sure to communicate their potential value. From rumors of pharmaceutical acquisitions to questions over cash, biotechnology companies are facing increasing pressure to communicate their economic position, as well as the depth of their drugs and therapy pipeline. “I think it's better to let people know how you're dealing with challenges than to pretend that there's nothing there,” says Jeff Rona, chief business officer for GlobeImmune, a privately held biopharmaceutical company that is developing therapies to treat hepatitis C and pancreatic cancer. The Boulder, CO-based company hired Russo Partners in summer 2008 to prepare for the release of data for its targeted immunotherapies at the American Association for the Study of Liver Diseases conference last November.
|
|
|
|
|
|
|
Briefings help educate reporters on products and topics - Jaimy Lee
Date: March 16, 2009
Summary: Many Companies provide background and insight to hournalists via meetings in one-on-one and group settings. But for health companies, such sessions are especially useful. Device-provider Radi Medical Systems invited a Wall Street Journal reporter, who was seeking information about inventional cardiology procedures, to a hospital to observe a procedure and speak with cardiologists, acording to David Schull, president of Russo Partners, which works with Radi.
|
|
|
|
|
|
|
Russo Partners Adds Three Clients - Jaimy Lee
Date: March 12, 2009
Summary: NEW YORK: Russo Partners announced three client wins in March, including Regulus Therapeutics, Savara Pharmaceuticals, and Amira Pharmaceuticals. The firm is developing media relations programs for all three companies.
|
|
|
|
|
|
"Molecular Insight Pharmaceuticals Hires Russo" - Jaimy Lee
Date: February 2, 2009
Summary: CAMBRIDGE, MA: Molecular Insight Pharmaceuticals tapped Russo Partners for media relations support, following an informal review. The New York-based firm will create a media plan to raise awareness about the company and its product with investor, pharmaceutical, and medical communities. Work began January 19. The Cambridge, MA-based biopharmaceutical company develops radiotherapeutics for oncology and cardiology.
|
|
|
|
|
|
"Company cleared for first clinical trial with human stem cells reaches out" - Jaimy Lee
Date: January 29, 2009
Summary: Geron, a biopharmaceutical company, is working with Russo Partners on the company's clearance by the Food and Drug Administration (FDA) to start the first clinical trial using human embryonic stem cells. The PR team used a tiered approach to release news of the clearance on January 23, said David Schull, President of Russo Partners. The New York-based firm has provided corporate communications and IR support for Geron since 2007.
|
|
|
|
|
|
"Russo Partners forms alliance with Blue State Digital"
Date: January 12, 2009
Summary: Russo Partners formed an exclusive alliance with Blue State Digital, the firm behind President-elect Barack Obama's Web campaign, the agency announced January 12. The purpose, said Tony Russo, president and CEO of Russo Partners, is to help the agency's pharmaceutical and biotechnology clients 'develop a Web 2.0 strategy.'
|
|
|
|
|
|
"CorNova names Russo Partners AOR" - Jaimy Lee
Date: December 17, 2008
Summary: CorNova, a medical device company, hired Russo Partners as its first AOR, effective December 12. The New York-based agency is providing message development, media relations, executive visibility, and IR to help CorNova meet its fundraising and business development goals.
|
|
|
|
|
|
"Market Focus: Healthcare - Prescription for a new dialogue" - Erica Iacono and Jaimy Lee
Date: December 1, 2008
Summary: Leading PR pros from a variety of firms, companies, and other organizations will gather in a roundtable discussion about the issues affecting them and their peers. Tony Russo talks about election impact, communicating risk, social media (Web 2.0) and internal communications.
|
|
|
|
|
|
"CorNova names Russo Partners AOR" - Jaimy Lee
Date: August 10, 2007
Summary: As the debate surrounding the future of medical stents continues to pick up steam, Radi Medical Systems has kicked off a major education campaign for its PressureWire device, intended to help doctors determine whether stents are required in a given patient. Russo Partners was brought on to handle the national communications effort in July and will begin by reaching out to cardiologists and payers to explain the benefits of measuring coronary artery pressure when determining whether stents are necessary.
|
|
|
|
 |
|
"Executive Profile: David Schull" - Katie Weeks
Date: December 18, 2006
Summary: David Schull's career as a public relations executive for international life sciences publicity firm Noonan Russo began, ironically, during his second year of law school in the early 1990s. About a year ago, Schull started a West Coast office near La Jolla for New York-based Noonan Russo. In the past year, he has grown the office to six employees, and says the firm is turning away more clients than it accepts.
|
|
|
|
 |
|
"Building a Sound Communications Foundation for a Venture Capital Audience"
Date: November/December 2006
Summary: Dr. Tony Russo talks straight about the importance of having a clear message and position and how conveying them effectively to a VC investor can guarantee funding.
|
|
|
|
|
|
"When the big story is a secret" - Celeste Altus
Date: July 31, 2006
Summary: It was only three years ago that La Jolla, CA-based biotech company Ambrx was a few scientists and an idea. Now in 2006, it is a full-fledged biopharmaceutical firm with more than 50 employees; a new CEO, Martin Mattingly, formerly of CancerVax; and a mission to deliver breakthrough protein therapeutics. It wasn't a short path, but Mattingly understood that one of the vital roles he had to play as CEO was a marketing and communications one. The company's visibility began to take flight when Ambrx hired biotech specialist Noonan Russo...
|
|
|
|
 |
|
"The Secure IPO Launch Plan - A Virtual Roundtable" - Wayne Koberstein
Date: June 2005
Summary: This special report serves as a practical guide for biotech companies planning an initial public offering - and for avoiding self-created complications in the process. It brings together a panel of seven IPO experts, including Tony Russo, who talks about his years of experience in dealing with IPOs.
|
|
|
|
 |
|
"PR View" - Anthony Russo
Date: September 2004
Summary: Summary: All too often I hear product managers say they consider public relations to be a "nice to have but not critical" part of their marketing mix. Others tell me they have a small product with a small budget and can't afford a PR program. I would argue that they can't afford not to have a public relations program.
|
|
